Mario Gabelli Vertex Pharmaceuticals Inc Transaction History
Gamco Investors, Inc. Et Al
- $9.45 Billion
- Q3 2025
A detailed history of Mario Gabelli (Gamco Investors, Inc. Et Al) transactions in Vertex Pharmaceuticals Inc stock. As of the latest transaction made, Gamco Investors, Inc. Et Al holds 512 shares of VRTX stock, worth $222,218. This represents 0.0% of its overall portfolio holdings.
Number of Shares
512
Previous 512
-0.0%
Holding current value
$222,218
Previous $227,000
11.89%
% of portfolio
0.0%
Previous 0.0%
Shares
1 transactions
Others Institutions Holding VRTX
# of Institutions
1,787Shares Held
231MCall Options Held
1.83MPut Options Held
1.21M-
Capital World Investors Los Angeles, CA25.9MShares$11.2 Billion1.45% of portfolio
-
Vanguard Group Inc Valley Forge, PA24.2MShares$10.5 Billion0.15% of portfolio
-
Black Rock Inc. New York, NY21.3MShares$9.25 Billion0.23% of portfolio
-
Capital Research Global Investors Los Angeles, CA16.6MShares$7.18 Billion1.27% of portfolio
-
State Street Corp Boston, MA11.6MShares$5.04 Billion0.16% of portfolio
About VERTEX PHARMACEUTICALS INC
- Ticker VRTX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 256,691,008
- Market Cap $111B
- Description
- Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAF...